|Event Date/Time: Nov 29, 2004||End Date/Time: Nov 30, 2004|
Aventis, GPC Biotech, Pfizer, Cancer Research Technology, Biovex, De Novo
Pharmaceuticals, Cambridge Healthcare & Biotech, Amersham Biosciences, Bayer Cropscience and AstraZeneca.
You will also hear from many of the leading lawyers in private practice. The conference will address a range of relevant issues and subjects including:
• Pharma and Biotech perspectives on valuation
• Expert advice on how to conduct your due diligence successfully
• A detailed analysis of a license agreement
• The key considerations when drafting royalties
• The licensing impact of EU enlargement
C5's conference on BioPharm Licensing is the one stop shop for anyone involved in licensing biotechnology to gain the updates, insights and expert knowledge required to stay ahead of the game.
EF International has changed its name to C5 to reflect the consolidation of its 5 conference groups across 5 continents.